Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joep Killestein

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|October 4, 2002
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitusJoep Killestein
Lancet (London, England)|June 13, 2003
ASCOT-LLA: questions about the benefits of atorvastatinJoep Killestein
The New England Journal of Medicine|December 18, 2015
Cannabinoids in the Treatment of EpilepsyJoep Killestein
The New England Journal of Medicine|February 12, 2005
Carotid-artery stenting versus endarterectomyJoep Killestein
Neurology|April 7, 2021
Quelling Public Fears About Guillain-Barré Syndrome and COVID-19 VaccinationDennis Bourdette, Joep Killestein
Neurology. Clinical Practice|September 6, 2021
Loss of Neurologic Reserve in Progressive Multiple Sclerosis: A Paradigm Shift?Joep Killestein, Maria Liguori
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 26, 2004
The therapeutic value of cannabinoids in MS: real or imaginary?Joep Killestein, Chris Polman
Lancet (London, England)|May 18, 2004
Statins for the treatment of multiple sclerosis: cautious hopeChris H Polman, Joep Killestein
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 10, 2015
Low JC virus antibody index during natalizumab treatment less safe than assumed?Joep Killestein, Mike P Wattjes
Current Opinion in Neurology|May 14, 2005
Current trials in multiple sclerosis: established evidence and future hopesJoep Killestein, Chris H Polman
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|October 4, 2002
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitusJoep Killestein
Lancet (London, England)|June 13, 2003
ASCOT-LLA: questions about the benefits of atorvastatinJoep Killestein
The New England Journal of Medicine|December 18, 2015
Cannabinoids in the Treatment of EpilepsyJoep Killestein
The New England Journal of Medicine|February 12, 2005
Carotid-artery stenting versus endarterectomyJoep Killestein
Neurology|April 7, 2021
Quelling Public Fears About Guillain-Barré Syndrome and COVID-19 VaccinationDennis Bourdette, Joep Killestein
Neurology. Clinical Practice|September 6, 2021
Loss of Neurologic Reserve in Progressive Multiple Sclerosis: A Paradigm Shift?Joep Killestein, Maria Liguori
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 26, 2004
The therapeutic value of cannabinoids in MS: real or imaginary?Joep Killestein, Chris Polman
Lancet (London, England)|May 18, 2004
Statins for the treatment of multiple sclerosis: cautious hopeChris H Polman, Joep Killestein
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 10, 2015
Low JC virus antibody index during natalizumab treatment less safe than assumed?Joep Killestein, Mike P Wattjes
Current Opinion in Neurology|May 14, 2005
Current trials in multiple sclerosis: established evidence and future hopesJoep Killestein, Chris H Polman
Pageof 28